Boston Immune Technologies & Therapeutics

0 followers

‌

BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.

Industries

Biotechnology, Therapeutics

Headquarters

Winchester, United States

Employees

1-10

Links

Org chart

Russell LaMontagne

CEO

Russell LaMontagne

Collapse

David Brooks

Chief Medical Officer

VP of Manufacturing

Finance Director

Director of Legal

Director of Preclinical Development

Mohammad Razvi

Director of Clinical Operations & Development

Teams

This company has no teams yet

Similar companies

Thermo Fisher Scientific

166 followers

Genentech

150 followers

Biogen

114 followers

Illumina

67 followers

Agilent Technologies

63 followers

Avantor

10 followers

Promega

8 followers

United Therapeutics

7 followers

Calico

6 followers

Sage Therapeutics

5 followers

Pfizer

483 followers

Explore companies